default author photo

Tsogjargal Burentogtokh

First Central Hospital of Mongolia - General Laboratory of Clinical Pathology

SCHOLARLY PAPERS

1

DOWNLOADS

123

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Immunogenicity, Safety, and Reactogenicity of a Half- Versus Full-Dose BNT162b2 (Pfizer-Biontech) Booster Following a Two-Dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac Priming Schedule in Mongolia: A Randomised, Controlled, Non-Inferiority Trial

Number of pages: 25 Posted: 03 Apr 2023
National Center for Communicable Diseases, University of Melbourne - Infection and Immunity, University of Melbourne - Infection and Immunity, Onoshmed Laboratory, National Center for Communicable Diseases, Onoshmed Laboratory, Sukhbaatar District Health Centre, First Central Hospital of Mongolia - General Laboratory of Clinical Pathology, University of Melbourne - Infection and Immunity, First Central Hospital of Mongolia - General Laboratory of Clinical Pathology, University of Melbourne - Infection and Immunity, Mongolian National University of Medical Sciences, University of Melbourne - Infection and Immunity, Bayangol District Health Centre, First Central Hospital of Mongolia - General Laboratory of Clinical Pathology, University of Melbourne - Infection and Immunity, University of Melbourne - Infection and Immunity, University of Melbourne - Murdoch Children's Research Institute, National Center for Communicable Diseases, University of Melbourne - Murdoch Children's Research Institute, University of Melbourne - Infection and Immunity, University of Melbourne - Infection and Immunity, Ministry of Health, Mongolia, National Center for Communicable Diseases, Onoshmed Laboratory, National Centre for Public Health (Mongolia), University of Melbourne - Infection and Immunity and University of Melbourne - Infection and Immunity
Downloads 123 (584,619)

Abstract:

Loading...

COVID-19, SARS-CoV-2, vaccination, fractional dose, half-dose, booster, BNT162b2